Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience
Annals of the Rheumatic Diseases, ISSN: 0003-4967, Vol: 67, Issue: 5, Page: 717-719
2008
- 47Citations
- 45Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations47
- Citation Indexes46
- 46
- CrossRef38
- Clinical Citations1
- PubMed Guidelines1
- Captures45
- Readers45
- 45
Article Description
To investigate the response to biologic drugs in psoriatic arthritis and to quantify non-response and outcome from switching agents. 60 patients (33 men and 27 women, mean age 46 years, median disease duration 16 years) prescribed biologic drugs for psoriatic arthritis between 2001 and 2006 were studied. Response was evaluated using joint counts, C-reactive protein levels and disease activity scores (using 28 joints; DAS28). The mean percentage improvements seen were 56% in tender joint count, 70% in swollen joint count, 64% in C-reactive protein level and 36% in the overall disease activity score. Improvements were sustained beyond 24 months with no loss of effect. Side-effects leading to cessation or switching of first-line therapy were only seen in 5% of patients and non-response occurred in 20% long term. Overall, 90% of patients achieved a significant response, using switching in 20% of cases. Outcomes were similar regardless of drug used, duration of disease and subtype of arthritis. Treatment of active psoriatic arthritis with anti-tumour necrosis factor agents leads to a sustained response over 3 years with most patients tolerating these drugs well. The rate of non-response is low with the majority of patients responding to second- and third-line therapies.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0003496724218173; http://dx.doi.org/10.1136/ard.2007.082925; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=42449160970&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/18055476; https://linkinghub.elsevier.com/retrieve/pii/S0003496724218173; https://dx.doi.org/10.1136/ard.2007.082925; https://ard.bmj.com/content/67/5/717
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know